Page last updated: 2024-11-08

triiodothyronine and Multiple Sclerosis, Relapsing-Remitting

triiodothyronine has been researched along with Multiple Sclerosis, Relapsing-Remitting in 1 studies

Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.
3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.

Multiple Sclerosis, Relapsing-Remitting: The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see OPTIC NEURITIS), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Monzani, F1
Caraccio, N1
Casolaro, A1
Lombardo, F1
Moscato, G1
Murri, L1
Ferrannini, E1
Meucci, G1

Trials

1 trial available for triiodothyronine and Multiple Sclerosis, Relapsing-Remitting

ArticleYear
Long-term interferon beta-1b therapy for MS: is routine thyroid assessment always useful?
    Neurology, 2000, Aug-22, Volume: 55, Issue:4

    Topics: Adult; Autoantibodies; Drug Administration Schedule; Female; Humans; Interferon beta-1a; Interferon

2000